Clinical Trial Update: An Open-label, Phase I Clinical Trial of Super1 TCR-T in NY-ESO-1-positive Patients With Advanced Solid Tumors [Phase 1]

View source ↗

Summary

Open-label Phase I trial of Super1 TCR-T therapy targeting NY-ESO-1 in patients with advanced solid tumors, currently recruiting.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Lung Cancer
• Melanoma
• Sarcoma

Drugs mentioned

• Super1 TCR-T

Snippet

Sponsor: Guangzhou FineImmune Biotechnology Co., LTD. | Conditions: Sarcoma, Lung Cancers | Phase 1 | Status: RECRUITING